Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Joseph Bass, MD, PhD

Division Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare
Member of the Healthcare Council

Joseph Bass, MD, PhD, is Assistant Professor of Medicine and Neurobiology at Northwestern University in Illinois and Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare. He is also the Director of a federally-funded basic research program on obesity, diabetes, and lipid disease at Northwestern. Dr. Bass has expertise in treatment of obesity, diabetes, hypertension, and hypercholesterolemia, as well as evaluation of pre-clinical drug discovery. He oversees the largest clinical endocrinology practice division in the US, and is also active in new applications of DPP-IV inhibitors, incretins (Byetta, LAR, liraglutide), MCH inhibitors, and melanocortinergic modulators. Dr. Bass consults on obesity and diabetes drug discovery for the biotechnology and pharmaceutical industries and has co-founded two companies in diabetes and obesity compound development. (This is me - Update Profile)


Employment History
1999 - present Division Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare
1999 - present Assistant Professor of Medicine and Neurobiology
Northwestern University
1993 - 1999 Instructor of Medicine
University of Chicago

GLG Study Groups with Joseph Bass, MD, PhD(?)

View All Study Groups with Joseph Bass, MD, PhD

GLG NewsSM Analyses by Joseph Bass, MD, PhD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Another Glinide: Where's the Beef? | 03-28-2008
Analysis of: Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes.  With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel...

Warning on A1C Targets and Diabetes Death in ACCORD Trial | 02-08-2008
Analysis of: Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.

Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia | 02-05-2008
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Oral therapies improve complianceEU approval of Galvus does not erase US doubts

Alogliptin on the diabetes horizon. | 01-09-2008
Analysis of: Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | www.pipelinereview.com
Author: Joseph Bass, MD, PhD, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare

Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.

GLG InstituteSM Seminars with Joseph Bass, MD, PhD(?)

 
Joseph Bass, MD, PhD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Joseph Bass, MD, PhD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-05T09:45:16.717